Abbott to separate Nutrition business into independent, publicly traded company
Abbott plans to spin off its global Nutrition business, which has about $8.5 billion in annual sales, into a separate public company through a tax-free distribution to Abbott shareholders. Abbott expects the separation to be completed by the end of 2027, subject to conditions including regulatory approvals and final board approval, and says it will not affect Abbott's 2026 guidance.
Key points
- Nutrition business has approximately $8.5 billion in annual sales, about 16,000 employees and 14 manufacturing sites
- Abbott will keep sales of approximately $42 billion after the separation
- Separation expected to be completed by the end of 2027; Abbott expects one-time transaction charges, not yet quantified
- Daniel Salvadori will become chief executive officer of the new Nutrition company
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.